| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
4 analysts have expressed a variety of opinions on Veracyte (NASDAQ:VCYT) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 0 | 1 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 1 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $27.25, with a high estimate of $33.00 and a low estimate of $21.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.84%.
A clear picture of Veracyte's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mike Matson | Needham | Lowers | Buy | $27.00 | $33.00 |
| Matthew Sykes | Goldman Sachs | Lowers | Buy | $28.00 | $32.00 |
| Tejas Savant | Morgan Stanley | Lowers | Underweight | $21.00 | $22.00 |
| Mike Matson | Needham | Raises | Buy | $33.00 | $30.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Veracyte's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Veracyte analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Veracyte's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2023, the company achieved a revenue growth rate of approximately 22.29%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Veracyte's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -28.81%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Veracyte's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.7%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Veracyte's ROA excels beyond industry benchmarks, reaching -2.53%. This signifies efficient management of assets and strong financial health.
Debt Management: Veracyte's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VCYT
